Nasdaq
$49.07▼ 1.54%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $1.34BShares out 27.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
25- 10.14Pre-market26.10.14 20:158-KKey event#●●●#●●●#●●●
Eton Pharmaceuticals, Inc.Bullish
Eton Pharmaceuticals has entered into an exclusive U.S. license and supply agreement with Aquestive Therapeutics for the seizure cluster treatment LIBERVANT. Eton paid an upfront fee of $10 million and is committed to up to $47.5 million in potential regulatory and commercial milestone payments, with a commercial launch anticipated in April 2027.…more
$49.07-1.54%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.6After-hours26.10.07 05:494Ownership
Eton Pharmaceuticals, Inc.
Insider David Krempa of Eton Pharmaceuticals reported a change in beneficial ownership of securities on October 6, 2026. This filing provides the details of the insider transaction in accordance with Form 4.…more
$49.07-1.54%vs prev closeView filingShare - 10.6After-hours26.10.07 05:05144Ownership
Eton Pharmaceuticals, Inc.
David Krempa, an insider at Eton Pharmaceuticals, Inc., has filed a Form 144 to report the proposed sale of company securities. This is a standard regulatory filing indicating an insider's plan to dispose of shares.…more
$49.07-1.54%vs prev closeView filingShare
24 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.14Regular26.10.15 02:34#●●●#●●●#●●●
Eton Pharmaceuticals Secures US Rights for Seizure Drug LIBERVANT
Eton Pharmaceuticals has entered into an exclusive licensing agreement for the U.S. commercialization of Aquestive Therapeutics' seizure cluster treatment, LIBERVANT. The company plans to launch the product in April 2027, marking its strategic expansion into the neurology market.…more
$49.07-1.54%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.14Pre-market26.10.14 19:50
●●●●●●●● ●●●●● ●●●●●●
Eton Pharmaceuticals has entered into an exclusive U.S. licensing and supply agreement with Aquestive Therapeutics for the seizure rescue treatment LIBERVANT. The company anticipates a commercial launch in April 2027, pending final FDA approval and market conditions.…more
$49.07-1.54%vs prev close - 9.28Pre-market26.09.28 19:50
●●●●●●●● ●●●●● ●●●●●●
Eton Pharmaceuticals has announced the U.S. commercial availability of its rare disease treatment, IMPAVIDO. The company is supporting the launch with a dedicated patient assistance program and centralized specialty pharmacy distribution.…more
$49.07-1.54%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report